Since several previous studies demonstrated that FXR agonists impeded liver fibrosis and inhibited hepatocyte apoptosis [38,39,40], FXR activation might partly contribute to the anti-fibrotic efficacy of cycloastragenol. Here, NR1H4 is linked to Hepatic fibrosis.